
Coordination key to tackling rise in livestock diseases, says WOAH
In recent years, European farmers have faced the emergence of previously unknown animal diseases, such as lumpy skin disease (LSD), and the return of others once eradicated, like foot-and-mouth disease. In Greece, sheep and goat pox has been declared a national emergency, while periodic waves of bird flu and African swine fever have been hitting the continent since 2014.
According to Arroyo, the growing frequency of outbreaks requires adapting to a new reality.
What follows is an edited transcript.
What factors contribute to the emergence of diseases such as LSD in Europe, as seen in France and Italy?
In the case of LSD, we don't yet know exactly where it originated. Epidemiological investigations are ongoing. More broadly, the risk of disease incursions is rising due to climate change, trade evolutions, and changes in pathogen dynamics. These three factors are driving the emergence of diseases in places where they did not previously exist.
Could you elaborate on how these factors impact animal diseases?
For LSD, climate change certainly plays a role. It's a vector-borne disease, primarily transmitted by vectors such as mosquitoes, ticks or flies. Temperature changes can enable these vectors to appear in areas where they were not previously present. In some cases, even extreme winds can transport them from one region to another.
What about trade?
Other possible origins of these outbreaks include transmission by an infected animal from an affected country or by imported equipment that has not been properly disinfected. We are seeing diseases emerge as a result of shifting consumption patterns. As populations move, their consumption habits and demand for certain products or animals change - and so do the associated risks.
Generally, we hope all countries apply the correct trade measures. However, travellers sometimes bring in products from their countries without complying with the sanitary restrictions designed to prevent this. In some countries, we're seeing an increase in illegal trade, which further increases the risks.
You also mentioned changes in pathogen dynamics. What does that mean?
Diseases evolve and adapt. Take avian influenza, for example: it used to only affect domestic poultry, but it has since evolved and spread to certain wild bird populations. This increases the risk to domestic animals when they come into contact with wildlife. We just need to monitor how pathogens are moving, understand how they affect different species, and try to respond accordingly.
We've also seen the emergence of other diseases like foot-and-mouth disease, African swine fever, and bluetongue. Is this part of a broader upward trend?
There have always been epidemics. But yes, we can say there has been an increase in outbreaks of diseases that were not previously present in the region. For example, it is the first time LSD has appeared in Continental Europe.
Do these outbreaks have a lasting impact on farms, and do they pose a growing threat to the EU's food security?
There are two types of impact: a direct one on producers, who are often severely affected, and a broader one on the country, which can be less severe if the disease is quickly contained. Take the example of foot-and-mouth disease in Germany. Fortunately, the impact was minor and well controlled because the disease was quickly identified and contained.
But some countries are unable to respond as quickly. This is sometimes because they do not have access to vaccines or because their veterinary services are not sufficiently supported. In Europe, resilience is quite good.
What does the WOAH recommend for managing disease outbreaks?
The only way to prevent a costly outbreak is to invest in veterinary services. In addition, we recommend establishing strong surveillance and early warning systems. It's also important to strengthen biosecurity, implement vector control measures, and carry out vaccination. And, of course, coordination between countries is essential.
Is the EU's regionalist approach, which focuses on affected regions rather than entire countries, a good method?
The regionalisation approach is an excellent tool. It can even be used to open markets when only half of a country is free of a particular disease.
The EU did not apply this measure to Brazil when it blocked poultry and meat exports to the bloc due to bird flu. What is your view on this?
Europe has very strict regulations on regionalisation. These apply to third countries but are based on the EU's risk assessment and the information those countries provide.
(adm, de)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Euractiv
3 days ago
- Euractiv
Roche steps in as Trump aims for 1500% drug price cuts
'We're gonna get the drug prices down – not 30% or 40%. No, we're gonna get them down 1,000%, 1,500%,' said the US president. Euractiv is part of the Trust Project Thomas Mangin Euractiv Jul 24, 2025 15:17 2 min. read News Based on facts, either observed and verified directly by the reporter, or reported and verified from knowledgeable sources. Amid a crusade against overpriced medicine, US President Donald Trump has promised to bring drug prices down by 1,500%. While the world still puzzles over his maths, the industry appears ready to offer solutions. 'We're gonna get the drug prices down – not 30% or 40%, which would be great. Not 50% or 60%. No, we're gonna get them down 1,000%, 600%, 500%, 1,500%,' said the US president at the White House on 22 July 22. 'Numbers that are not even thought to be achievable, because I've used a certain talent that I have,' he added. The pharmaceutical industry remains one of President Trump's primary targets. In his first term, Trump vowed to lower drug prices – but with little effect. A study by the Rand Corporation estimated that in 2024, drug prices in the United States were 2.7 times higher than in the 32 other OECD countries. The U.S. president continues to put pressure on big pharma groups and is pushing them to relocate to the United States, notably by threatening to impose tariffs of up to 200%. Several European companies have announced massive investments across the Atlantic in recent months. On 22 July, AstraZeneca unveiled a $50 billion investment plan in the United States by 2030. In April, Roche announced a similar investment for production as well as research and development in the U.S. 'We hope the U.S. government will see, through all the investments we and other companies are making, that pharmaceutical firms want to produce the medicines needed in the United States, for the United States,' said Schinecker. (bms, aw)


Euractiv
4 days ago
- Euractiv
Coordination key to tackling rise in livestock diseases, says WOAH
Surveillance, early warning systems and cross-border cooperation are essential to combat climate change, trade and pathogens adaptation that are driving a rise in animal diseases in Europe, says Montserrat Arroyo, Deputy Director General of the World Organisation for Animal Health (WOAH). In recent years, European farmers have faced the emergence of previously unknown animal diseases, such as lumpy skin disease (LSD), and the return of others once eradicated, like foot-and-mouth disease. In Greece, sheep and goat pox has been declared a national emergency, while periodic waves of bird flu and African swine fever have been hitting the continent since 2014. According to Arroyo, the growing frequency of outbreaks requires adapting to a new reality. What follows is an edited transcript. What factors contribute to the emergence of diseases such as LSD in Europe, as seen in France and Italy? In the case of LSD, we don't yet know exactly where it originated. Epidemiological investigations are ongoing. More broadly, the risk of disease incursions is rising due to climate change, trade evolutions, and changes in pathogen dynamics. These three factors are driving the emergence of diseases in places where they did not previously exist. Could you elaborate on how these factors impact animal diseases? For LSD, climate change certainly plays a role. It's a vector-borne disease, primarily transmitted by vectors such as mosquitoes, ticks or flies. Temperature changes can enable these vectors to appear in areas where they were not previously present. In some cases, even extreme winds can transport them from one region to another. What about trade? Other possible origins of these outbreaks include transmission by an infected animal from an affected country or by imported equipment that has not been properly disinfected. We are seeing diseases emerge as a result of shifting consumption patterns. As populations move, their consumption habits and demand for certain products or animals change - and so do the associated risks. Generally, we hope all countries apply the correct trade measures. However, travellers sometimes bring in products from their countries without complying with the sanitary restrictions designed to prevent this. In some countries, we're seeing an increase in illegal trade, which further increases the risks. You also mentioned changes in pathogen dynamics. What does that mean? Diseases evolve and adapt. Take avian influenza, for example: it used to only affect domestic poultry, but it has since evolved and spread to certain wild bird populations. This increases the risk to domestic animals when they come into contact with wildlife. We just need to monitor how pathogens are moving, understand how they affect different species, and try to respond accordingly. We've also seen the emergence of other diseases like foot-and-mouth disease, African swine fever, and bluetongue. Is this part of a broader upward trend? There have always been epidemics. But yes, we can say there has been an increase in outbreaks of diseases that were not previously present in the region. For example, it is the first time LSD has appeared in Continental Europe. Do these outbreaks have a lasting impact on farms, and do they pose a growing threat to the EU's food security? There are two types of impact: a direct one on producers, who are often severely affected, and a broader one on the country, which can be less severe if the disease is quickly contained. Take the example of foot-and-mouth disease in Germany. Fortunately, the impact was minor and well controlled because the disease was quickly identified and contained. But some countries are unable to respond as quickly. This is sometimes because they do not have access to vaccines or because their veterinary services are not sufficiently supported. In Europe, resilience is quite good. What does the WOAH recommend for managing disease outbreaks? The only way to prevent a costly outbreak is to invest in veterinary services. In addition, we recommend establishing strong surveillance and early warning systems. It's also important to strengthen biosecurity, implement vector control measures, and carry out vaccination. And, of course, coordination between countries is essential. Is the EU's regionalist approach, which focuses on affected regions rather than entire countries, a good method? The regionalisation approach is an excellent tool. It can even be used to open markets when only half of a country is free of a particular disease. The EU did not apply this measure to Brazil when it blocked poultry and meat exports to the bloc due to bird flu. What is your view on this? Europe has very strict regulations on regionalisation. These apply to third countries but are based on the EU's risk assessment and the information those countries provide. (adm, de)


Euractiv
6 days ago
- Euractiv
AstraZeneca to invest $50 billion in US by 2030 amid Trump tariff fears
Anglo-Swedish pharma giant AstraZeneca announced on 21 July a $50 billion investment in the United States by 2030, amid threats of massive tariffs that the Trump administration could eventually impose. AstraZeneca CEO Pascal Soriot announced from Washington that the group would invest around $50 billion in the United States over the next five years to expand its production capacity across the Atlantic. According to the company, this would enable it to reach $80 billion in revenue, with half of that figure generated in the United States. The investments will support the construction of a new drug manufacturing facility in Virginia and the expansion of existing research centres in Maryland, Massachusetts, California, Indiana, and Texas. These investments follow a trend observed among other major companies in recent months, such as Roche – which has also signalled plans to invest around $50 billion in the US – as well as Novartis, Sanofi, and Johnson & Johnson. Analysts, however, noted that most of those investments had been in the pipeline for some time. In Brussels, these announcements heightened fears of a potential exodus of major pharmaceutical companies across the Atlantic. Trump threatened to impose 200% tariffs The direction of these investments is largely driven by threats from the Trump administration to impose massive tariffs on the pharmaceutical sector. In recent months, the US president has repeatedly stated his intention to boost domestic drug manufacturing, citing a significant deficit in this area. One-third of European exports to the US are pharmaceuticals, with the EU generating a €70 billion trade surplus in the sector. To address this imbalance, Trump threatened as recently as July to impose a 200% tariff on certain medicines, declaring that manufacturers would have "one to two years" to bring production back to the US. 'For decades, Americans have depended on foreign countries for essential pharmaceutical supplies. President Trump and our new tariff policies aim to correct this structural weakness,' commented US Commerce Secretary Howard Lutnick. 'We are proud that AstraZeneca has chosen to relocate a significant portion of its pharmaceutical production,' he added. While tariffs have played a role in AstraZeneca's decision-making, the company had already prioritised the United States as a key market even before Trump's return to the Oval Office. In 2024, the Anglo-Swedish firm generated 40% of its revenue in the US. (bms, aw)